Hikal (HIKAL)₹225.40+2.18%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Hikal reported sales of ₹403 Cr, up 6.0% from Jun 2025, and net profit of −₹7.39 Cr. For the year to Mar 2026, sales were ₹1,714 Cr and net profit −₹48.95 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 435 | 448 | 515 | 407 | 453 | 448 | 553 | 380 | 319 | 495 | 520 | 403 |
| Expenses | 378 | 383 | 421 | 349 | 379 | 376 | 430 | 356 | 312 | 412 | 415 | 366 |
| Operating Profit | 57.61 | 64.77 | 94.45 | 58.04 | 74.98 | 72.16 | 123 | 25.11 | 7.21 | 82.82 | 105 | 37.02 |
| OPM % | 13.2% | 14.4% | 18.3% | 14.2% | 16.5% | 16.0% | 22.3% | 6.6% | 2.3% | 16.7% | 20.2% | 9.2% |
| Other Income | 0.98 | 0.09 | 0.49 | 0.49 | 0.39 | 3.59 | 0.49 | 0.99 | 1.89 | −35.10 | −40.40 | 10.67 |
| Interest | 13.07 | 14.19 | 15.27 | 19.78 | 18.77 | 18.68 | 17.86 | 17.09 | 14.88 | 15.48 | 14.59 | 14.87 |
| Depreciation | 28.65 | 29.07 | 32.39 | 31.88 | 31.80 | 33.30 | 37.82 | 39.50 | 41.31 | 41.31 | 42.09 | 42.82 |
| Profit before tax | 16.91 | 21.66 | 47.43 | 6.92 | 24.87 | 23.89 | 68.54 | −30.49 | −47.19 | −9.23 | 8.32 | −9.93 |
| Tax % | 25.5% | 25.5% | 28.4% | 26.1% | 26.3% | 27.8% | 26.5% | −26.3% | −25.8% | −35.9% | −73.5% | −25.2% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −37.89 | −46.99 | 8.88 |
| Net Profit | 12.55 | 16.07 | 33.87 | 5.09 | 18.27 | 17.17 | 50.09 | −22.36 | −34.84 | −5.89 | 14.39 | −7.39 |
| EPS (Rs) | 1.03 | 1.32 | 2.76 | 0.42 | 1.49 | 1.40 | 4.08 | −1.83 | −2.84 | −0.49 | 1.18 | −0.61 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 927 | 1,015 | 1,298 | 1,590 | 1,509 | 1,721 | 1,945 | 2,025 | 1,787 | 1,862 | 1,714 | 1,736 |
| Expenses | 746 | 814 | 1,056 | 1,294 | 1,236 | 1,400 | 1,605 | 1,768 | 1,522 | 1,533 | 1,494 | 1,505 |
| Operating Profit | 181 | 201 | 242 | 298 | 273 | 323 | 341 | 258 | 267 | 328 | 220 | 232 |
| OPM % | 19.9% | 19.9% | 18.9% | 19.0% | 17.9% | 18.9% | 17.9% | 13.0% | 15.0% | 18.0% | 13.0% | 13.4% |
| Other Income | 1.99 | −2.99 | 3.99 | 1.99 | −11.96 | 4.98 | 4.98 | 4.98 | 1.99 | 4.98 | −72.81 | −62.94 |
| Interest | 61.96 | 47.95 | 48.93 | 57.96 | 51.97 | 35.93 | 30.97 | 47.90 | 55.89 | 74.85 | 61.94 | 59.82 |
| Depreciation | 67.18 | 69.17 | 86.21 | 93.29 | 82.16 | 85.19 | 96.32 | 109 | 118 | 134 | 164 | 168 |
| Profit before tax | 53.20 | 80.20 | 112 | 150 | 127 | 207 | 220 | 105 | 96.25 | 124 | −78.21 | −58.03 |
| Tax % | 23.0% | 16.0% | 31.0% | 31.1% | 33.0% | 36.0% | 27.0% | 26.1% | 27.1% | 27.0% | −38.0% | — |
| Exceptional items | 0.00 | −4.99 | 0.00 | 0.00 | −9.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −84.81 | −76.00 |
| Net Profit | 40.96 | 67.90 | 76.88 | 103 | 83.81 | 133 | 160 | 77.93 | 69.94 | 90.80 | −48.95 | −33.73 |
| EPS (Rs) | 3.35 | 5.50 | 6.27 | 8.37 | 6.86 | 10.81 | 13.03 | 6.37 | 5.65 | 7.37 | −3.97 | −2.76 |
| Dividend payout % | 20.0% | 15.0% | 13.0% | 14.0% | 18.0% | 19.0% | 12.0% | 19.0% | 21.0% | 11.0% | −15.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.07 | 16.07 | 16.07 | 16.06 | 25.10 | 25.10 | 25.11 | 25.11 | 25.10 | 25.10 | 25.10 | 25.11 |
| Reserves | 518 | 549 | 591 | 656 | 735 | 795 | 913 | 1,047 | 1,113 | 1,168 | 1,243 | 1,179 |
| Borrowings | 549 | 506 | 600 | 637 | 662 | 648 | 612 | 676 | 750 | 820 | 767 | 686 |
| Other Liabilities | 213 | 207 | 178 | 238 | 269 | 307 | 372 | 472 | 506 | 484 | 504 | 485 |
| Total Liabilities | 1,297 | 1,279 | 1,384 | 1,548 | 1,692 | 1,775 | 1,920 | 2,221 | 2,394 | 2,496 | 2,539 | 2,374 |
| Fixed Assets | 641 | 625 | 670 | 636 | 716 | 738 | 716 | 883 | 951 | 1,074 | 1,369 | 1,338 |
| CWIP | 62.24 | 66.25 | 63.21 | 118 | 79.36 | 162 | 255 | 296 | 414 | 416 | 122 | 94.30 |
| Investments | 3.01 | 3.01 | 4.01 | 3.01 | 1.01 | 1.01 | 1.01 | 11.02 | 5.01 | 5.01 | 10.03 | 10.02 |
| Other Assets | 590 | 585 | 647 | 791 | 896 | 875 | 949 | 1,031 | 1,024 | 1,001 | 1,038 | 931 |
| Inventories | 314 | 291 | 264 | 303 | 364 | 312 | 267 | 329 | 317 | 304 | 334 | 358 |
| Trade receivables | 128 | 112 | 257 | 288 | 351 | 341 | 487 | 439 | 443 | 552 | 523 | 443 |
| Cash & equivalents | 13.96 | 18.97 | 15.97 | 26.94 | 31.95 | 63.84 | 36.90 | 48.89 | 59.91 | 20.94 | 17.95 | 13.97 |
| Total Assets | 1,297 | 1,279 | 1,384 | 1,548 | 1,692 | 1,775 | 1,920 | 2,221 | 2,394 | 2,496 | 2,539 | 2,374 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 102 | 186 | 163 | 139 | 186 | 286 | 229 | 295 | 316 | 187 | 280 | 303 |
| Cash from investing activity | −42.96 | −63.98 | −102 | −110 | −125 | −164 | −156 | −284 | −292 | −174 | −136 | −145 |
| Cash from financing activity | −68.71 | −123 | −62.77 | −24.92 | −54.79 | −101 | −96.55 | −5.98 | −7.97 | −26.91 | −143 | −159 |
| Net cash flow | −10.01 | −2.01 | −2.01 | 4.01 | 6.01 | 20.03 | −24.05 | 4.01 | 15.03 | −14.04 | 0.00 | −3.01 |
| Capex | 49.13 | 59.19 | 122 | 106 | 128 | 159 | 158 | 274 | 304 | 205 | 137 | 148 |
| Free cash flow | 54.10 | 127 | 58.09 | 33.08 | 57.12 | 127 | 71.12 | 21.06 | 13.04 | −17.03 | 144 | 154 |
| CFO / OP % | 63.1% | 110.0% | 91.0% | 68.0% | 73.1% | 113.0% | 85.1% | 107.0% | 134.0% | 81.1% | 94.0% | 144.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 53 | 43 | 91 | 80 | 79 | 81 | 102 | 81 | 79 | 112 | 102 | 93 |
| Inventory days | 268 | 229 | 189 | 158 | 156 | 147 | 107 | 121 | 104 | 134 | 146 | 172 |
| Days payable | 116 | 100 | 92 | 85 | 67 | 94 | 91 | 90 | 102 | 122 | 132 | 127 |
| Cash conversion cycle | 204 | 172 | 187 | 152 | 167 | 134 | 117 | 111 | 80 | 123 | 115 | 137 |
| Working capital days | −13 | 29 | 43 | 29 | 45 | 28 | 39 | 26 | 39 | 39 | 37 | 41 |
| ROCE % | 11.0% | 11.0% | 12.0% | 13.0% | 15.0% | 14.0% | 16.0% | 15.0% | 8.0% | 8.0% | 10.0% | 4.0% |
For the Jun 2026 quarter, Hikal reported sales of ₹403 Cr, up 6.0% year on year and net profit of −₹7.39 Cr. The operating margin was 9.2%.
Hikal's sales for the year to Mar 2026 were ₹1,714 Cr; over the last twelve months they were ₹1,736 Cr.
Net profit for the year to Mar 2026 was −₹48.95 Cr, and −₹33.73 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−2.76.
Hikal reported borrowings of ₹686 Cr at Mar 2026, against cash and equivalents of ₹13.97 Cr.
Cash from operations was ₹303 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹154 Cr.